Midhun Malla, MD

The final segment looks toward the future of mPDAC management, with a focus on the evolving role of KRAS inhibition across lines of therapy.

Maintaining patient functionality throughout long-term chemotherapy is one of the most critical and challenging goals in mPDAC management.

A 54-year-old female with pancreatic tail PDAC, bilateral nodules, a germline BRCA2 pathogenic variant, and a KRAS G12V somatic mutation presents a compelling case for molecularly informed treatment planning.

This segment centers on a 67-year-old male with ECOG PS 1 metastatic PDAC, a KRAS G12D mutation, elevated CA 19-9, and limited social support.

Translating clinical trial findings into everyday oncology practice requires nuanced judgment.

Choosing between triplet and doublet regimens requires careful individualization based on performance status, comorbidities, and disease burden. This segment examines the clinical factors guiding selection between NALIRIFOX and FOLFIRINOX, including peripheral neuropathy risk, GI tolerability, and the role of genomic mutations in sensitizing tumors to platinum-based or DNA-damaging agents.

The first-line treatment landscape for metastatic pancreatic ductal adenocarcinoma (mPDAC) has evolved significantly, yet options remain limited for this challenging disease. This opening segment explores how performance status, age, frailty, molecular profiling, and patient preferences drive treatment selection.

Drs Park and Malla discuss therapeutic options for patients with metastatic colorectal cancer, particularly in the third-line setting and beyond.

Chandler Park, MD and Midhun Malla, MD discuss treatment personalization in mCRC, with a focus on BRAF V600E–mutant tumors and HER2-altered disease.

Park and Malla discuss evolving approaches to colorectal cancer (CRC) management, with a focus on ctDNA, adjuvant therapy decision-making, and molecular profiling in metastatic disease.